Cardiotoxicity related to intrapericardial infusion of bevacizumab in the treatment of lung cancer-mediated malignant pericardial effusion: a case report
BackgroundLung cancer can result in malignant pericardial effusion (MPE), impacting patient prognosis. Intrapericardial infusion of bevacizumab was an alternative treatment for MPE.Case presentationWe present the case of a 48-year-old female with stage IV lung adenocarcinoma and MPE. MPE was managed...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2025-10-01
|
| Col·lecció: | Frontiers in Pharmacology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1573297/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|